{"type":"trials","record":{"id":21772,"source_id":"clinicaltrials-gov","external_id":"NCT06018467","title":"Senolytics to Improve Osteoporosis Therapy","brief_summary":"This randomised clinical trial aims to study osteoporosis as a disease of accelerated skeletal aging caused by the accumulation of senescent cells within the skeleton and investigate the effects and safety of senolytics and antioxidant therapy on bone.","overall_status":"Active Not Recruiting","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Odense University Hospital","enrollment":120,"countries":["Denmark"],"start_date":"2023-09-06","completion_date":"2026-04-30","last_update_date":"2026-05-11","source_url":"https://clinicaltrials.gov/study/NCT06018467","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-24T01:17:10.338673+00:00","last_seen_at":"2026-09-25T06:20:19.667+00:00","metadata":{"sex":"ALL","acronym":"SENIOR","age_range":"60 Years to 90 Years","comparator":"Control","organization":"Odense University Hospital","interventions":["Dasatinib 100 Mg Oral Tablet","Quercetin 1.250 mg (oral)","Nicotinamide Riboside 1g (oral)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Bone resorption marker CTX — Baseline, week 5, week 13, week 21","Bone resorption marker TRAcP — Baseline, week 5, week 13, week 21","Bone formation markers (PINP, osteocalcin, and bone alkaline phosphatase) — Baseline, week 5, week 13, week 21"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · SINGLE","source_has_results":false},"controlled_terms":["Osteopenia, Osteoporosis","Age-related Bone Loss","Dasatinib 100 Mg Oral Tablet","Quercetin 1.250 mg (oral)","Nicotinamide Riboside 1g (oral)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: senolytic.","quality_checked_at":"2026-09-25T06:20:27.00315+00:00","duplicate_cluster_key":"id:nct06018467","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-09-06 to 2026-04-30","comparator":"Control","confidence":"structured-source","population":"ALL · 60 Years to 90 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:19.685Z","intervention":["Dasatinib 100 Mg Oral Tablet","Quercetin 1.250 mg (oral)","Nicotinamide Riboside 1g (oral)"],"participants":120,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · SINGLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Bone resorption marker CTX — Baseline, week 5, week 13, week 21","Bone resorption marker TRAcP — Baseline, week 5, week 13, week 21","Bone formation markers (PINP, osteocalcin, and bone alkaline phosphatase) — Baseline, week 5, week 13, week 21"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"senolytics","is_published":true,"match_reasons":["Title contains controlled term: senolytic.","Abstract contains controlled term: senolytic, senescent cell.","Abstract supplies longevity context: aging.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Senolytics","slug":"senolytics"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/21772","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}